|Bid||6,320.00 x 20000|
|Ask||6,600.00 x 3500|
|Day's range||6,432.00 - 6,507.00|
|52-week range||5,255.00 - 7,890.00|
|PE ratio (TTM)||7.50|
|Earnings date||8 Feb 2018 - 12 Feb 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||6,916.32|
A U.S. court has granted Indivior (Swiss: OXINDV.SW - news) a preliminary injunction blocking India's Dr. Reddy's Laboratories from selling cut-price versions of the British drugmaker's best-selling opioid addiction treatment in the United States, Indivior (Frankfurt: 2IVA.F - news) said on Friday. Indivior, a maker of opioid addiction treatments spun-off from Reckitt Benckiser (Xetra: A0M1W6 - news) in 2014, has been involved in a number of legal battles with generic drugmakers over their versions of its Suboxone Film . Indivior got a temporary restraining order against Dr.Reddy's in June, but the British firm saw the impact from a generic in the market as Suboxone's market share dropped rapidly by 2.5 percent to 52 percent.
This FTSE 100 (INDEXFTSE: UKX) company could offer a favourable risk/reward opportunity along with another growth share.
Indivior Plc (Frankfurt: 2IVA.F - news) got a breather on Friday as a U.S. court extended a restraining order blocking a rival from launching a generic version of its bestselling opioid addiction treatment in the United States. Dr. Reddy's and U.S.-based Mylan NV received approval from the Food and Drug Administration (FDA) earlier this month to launch a generic version of Suboxone Film, which generates 80 percent of Indivior's revenue, forcing the UK company to file an injunction against the decision.
The blue chip FTSE 100 index closed down 0.1 percent at 7,615.63 points while the pan-European STOXX 600 fell 0.8 percent. "We seem to be hanging on the coattails of everything the White House says," said Ken Odeluga, market analyst at City Index. "The international flavor of the shares on the FTSE .... means that it should be very much impacted in the same way that you would expect large U.S. corporates on the S&P 500, the Dow Jones, to be impacted," Odeluga added, pointing to the fact that the FTSE is on track for a small loss for June.
Britain's Indivior (Frankfurt: 2IVA.F - news) on Friday vowed to pursue all legal options and seek an immediate injunction against the U.S. Food and Drug Administration's (FDA) decision to approve the first copycat versions of its best-selling opioid addiction treatment. India's Dr Reddy's Laboratories and U.S.-based Mylan NV received FDA approval on Thursday for a generic version of Suboxone Film, which generates 80 percent of Indivior's revenue. Generic rivals in tablet form are already on the U.S. market, which is grappling with an opioid addiction epidemic that killed 33,000 people in 2015, but Suboxone Film leads the market with its version which is placed under the tongue to suppress cravings.
Britain's Indivior (Frankfurt: 2IVA.F - news) said on Friday it would pursue all legal remedies, including seeking an immediate injunction against the U.S Food and Drug Administration's (FDA) decision to approve the first generic versions of Suboxone Film, an opioid addiction treatment. Indivior, which was spun out from Reckitt Benckiser (Xetra: A0M1W6 - news) in 2014, stuck to its 2018 guidance saying that until the details of Dr. Reddy's market entry of the drug's generic version is confirmed.
Britain's Indivior (Frankfurt: 2IVA.F - news) fell by more than 20 percent on Friday after the U.S Food and Drug Administration (FDA) approved the first generic versions of Suboxone Film, an opioid addiction treatment that generates 80 percent of its revenue. Shares (Berlin: DI6.BE - news) in Indivior, which was spun out from Reckitt Benckiser in 2014, were down 22.7 percent at 0925 GMT and the biggest loser on the FTSE midcap index. India's Dr Reddy's Laboratories received FDA approval for a copy-cat version of the treatment, which has been rapidly losing market share due to competition from generics.
Pharmapacks, an Islandia, N.Y.-based e-commerce site for health, beauty, personal care and household products, has secured $32.5 million in new funding.
Britain's Indivior (Frankfurt: 2IVA.F - news) has been subpoenaed by the California Department of Insurance over its blockbuster opioid addiction treatment, Suboxone Film, which is rapidly losing market share due to stiff competition from generic versions. Indivior said on Thursday the agency, which is charged with oversseing insurance regulations, requested documents from its U.S. unit relating to the preparation of the drug, manufacturing records, and the potential to develop dependency on the treatment. The investigation is one of several state and federal probes into the company's drug, which commands more than half the market and is suspected of being too aggressively promoted, delaying the market entry of generic rivals, and of being overprescribed by some doctors.
Beiersdorf's (BEIG.DE) sales growth was lifted by its Tesa adhesives unit and La Prairie premium skin care brand in the first quarter, smoothing slowing sales of its Nivea products. La Prairie sales jumped 56 percent as the German consumer goods firm reaped the benefits of a strategy to make its other businesses as strong as its mainstay Nivea brand. Luxury cosmetics are enjoying booming demand, particularly in China, which has also helped L'Oreal (OREP.PA) offset weaker performance in its mass market division.
Beiersdorf (IOB: 0DQ7.IL - news) 's sales growth was lifted by its Tesa adhesives unit and La Prairie premium skin care brand in the first quarter, smoothing slowing sales of its Nivea products. La Prairie sales jumped 56 percent as the German consumer goods firm reaped the benefits of a strategy to make its other businesses as strong as its mainstay Nivea brand. Beiersdorf said on Tuesday that its Tesa unit, which makes adhesives for the automotive and electronics industries, saw sales rise 8.5 percent and the medicinal Eucerin and Aquaphor lotions unit grew by 8.5 percent.
(Reuters) - National Grid (NG.L) Chief Financial Officer Andrew Bonfield is stepping down to take up a position with a U.S. public company, the British power grid operator said on Friday. Bonfield's move ...
National Grid Chief Financial Officer Andrew Bonfield is stepping down to take up a position with a U.S. public company, the British power grid operator said on Friday. Bonfield's move will help him be ...
Britain's Indivior (Frankfurt: 2IVA.F - news) posted a drop in first-quarter profit, as its blockbuster treatment, Suboxone Film, lost market share in the U.S. due to stiff competition from generic versions, the maker of drugs that treat opioid addiction said. Shares in Indivior, which was spun out from Reckitt Benckiser in 2014 and has risen about three-fold since, were down as much as 6 percent in early trading before clawing back most of it to trade 1.3 percent down on Wednesday.
British shares climbed on Friday after weaker than expected GDP data triggered a slide in sterling, while Royal Bank of Scotland shares fell after its first-quarter results. UK growth slowed much more ...
Russia and Syria presented more than a dozen unharmed people from Ghouta, Syria, at the premises of the Organisation for the Prohibition for Chemical Weapons on Thursday to support claims there was no chemical attack in the region this month. "The OPCW is not a theatre," Peter Wilson, Britain's envoy to the agency, said in a statement.
MKC reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.
Costa Coffee will be spun off after parent Whitbread yielded to pressure from hedge funds who argued it was being held back by being grouped with the Premier Inn hotel chain. The world's second biggest coffee chain after Starbucks Corp (Hanover: SRB.HA - news) has attractive, long-term international potential, Whitbread said. Former brewing group Whitbread will retain its Premier Inn hotels and Beefeater and Brewers Fayre restaurants once the split is completed within 24 months, a timeline which some shareholders said was longer than necessary.
Le borse europee sono deboli oggi, appesantite dai dati insoddisfacenti del gigante bancario svizzero Ubs e dal rialzo del rendimento dei bond. **Alle 10,25 italiane il paneuropeo STOXX 600 registra -0,24%. ...
** Reckitt Benckiser down 2.3 pct and bottom of FTSE 100 ** JPMorgan cuts TP by 200p to 7,000p and lowers FY adj EPS estimate by about 2 pct after co reported weak like-for-like sales growth on Friday ...
European shares fell on Monday as results from Switzerland's biggest bank, UBS, disappointed investors, and a rise in U.S. Treasury yields put pressure on bond-proxy sectors. The pan-European STOXX 600 ...
By Danilo Masoni and Kit Rees MILAN/LONDON (Reuters) - European shares held steady on Friday at the end of a strong week as a rally in commodities softened, although strong earnings updates boosted shares ...